Skip to main content
. 2019 Jan 25;110(2):617–628. doi: 10.1111/cas.13906

Figure 1.

Figure 1

Study design and patient allocation. Blue squares indicate inclusion for analysis, and gray squares indicate exclusion. cfDNA, cell‐free DNA; ctDNA, circulating tumor DNA; ddPCR, droplet digital PCR; NGS, next‐generation sequencing; RCC, renal cell carcinoma